title: Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients.
abstract: The effect of tenofovir (TDF) alone or in combination with interferon on hepatitis D virus (HDV) replication is poorly characterized in patients infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and HDV. We analyzed triinfected patients undergoing treatment with either TDF alone (n=13) or including interferon (IFN) at some point during TDF therapy (TDF+IFN, n=4). Linear mixed-effect models were used to estimate the mean change from baseline of HDV-RNA and hepatitis surface antigen (HBsAg) levels during treatment. Patients were followed for a median 31.6 (25-75%-tile: 15.0-47.4) months. In the TDF+IFN group, three initiated IFN-based therapy after a median of 21.7 months (range=10.5-24.9) of lamivudine (LAM)+TDF, while the remaining patient had 46.8 months of prior LAM exposure. Significant decreases in HDV-RNA were observed in both groups [TDF alone: -0.380 log10 copies/ml per year (95% CI: -0.557, -0.202) vs. TDF+IFN: -1.325 log10 copies/ml per year (95% CI: -1.931, -0.720)], while the HDV-RNA decline overall was significantly faster in patients with TDF+IFN (p=0.002). Accordingly, two patients achieved HDV-RNA below the limit of quantification (LOQ: <1,000 copies/ml) and one near LOQ (1450 copies/ml), all concomitantly treated with interferon. There were no significant changes in HBsAg levels for either group [TDF alone: -0.008 log10 IU/ml per month (95% CI: -0.019, 0.004), TDF+IFN:-0.011 log10 IU/ml per month (95% CI: -0.037, 0.015)] and no significant difference in slope between treatment groups (p=0.8). Interferon therapy might be more effective after extended previous anti-HBV antiviral exposure among triinfected patients; however, the long-term implications of these findings remain unknown.
authors: 1 Inserm, UMRS707, Paris, France .
authors: Anders
authors: A
authors: Boyd
authors: Patrick
authors: P
authors: Miailhes
authors: Ségolène
authors: S
authors: Brichler
authors: Caroline
authors: C
authors: Scholtès
authors: Sarah
authors: S
authors: Maylin
authors: Constance
authors: C
authors: Delaugerre
authors: Phillipe
authors: P
authors: Chevallier-Queyron
authors: Emmanuel
authors: E
authors: Gordien
authors: Pierre-Marie
authors: PM
authors: Girard
authors: Karine
authors: K
authors: Lacombe
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D005260:Female; D006678:HIV / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D003698:Hepatitis Delta Virus / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D057230:Limit of Detection; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000068698:Tenofovir; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D007372:Interferons; D000068698:Tenofovir; D000225:Adenine
references: Aliment Pharmacol Ther. 2012 Mar;35(6):663-73
references: 22273482
references: J Viral Hepat. 2008 Apr;15(4):314-21
references: 18307594
references: J Clin Microbiol. 2012 Jun;50(6):2126-8
references: 22422856
references: Hepatology. 1996 Aug;24(2):289-93
references: 8690394
references: J Clin Microbiol. 2005 May;43(5):2363-9
references: 15872267
references: J Hepatol. 2010 Nov;53(5):834-40
references: 20800919
references: AIDS. 2005 Jun 10;19(9):907-15
references: 15905671
references: J Med Microbiol. 2012 Dec;61(Pt 12):1780-1783
references: 22956751
references: J Clin Virol. 2010 Jan;47(1):97-9
references: 19914127
references: J Virol. 2010 Jun;84(12):5860-7
references: 20357083
references: AIDS. 2011 Oct 23;25(16):1987-92
references: 21857493
references: Eur J Gastroenterol Hepatol. 2009 Jan;21(1):28-38
references: 19060630
references: AIDS. 2012 May 15;26(8):939-49
references: 22333748
references: N Engl J Med. 2011 Jan 27;364(4):322-31
references: 21268724
references: J Clin Virol. 2012 May;54(1):93-5
references: 22365367
references: Lancet. 2011 Jul 2;378(9785):73-85
references: 21511329
references: Clin Infect Dis. 2007 Sep 1;45(5):624-32
references: 17682999
references: Antivir Ther. 2008;13(1):97-102
references: 18389903
references: Hepatology. 2011 Jun;53(6):2131-3
references: 21618261
references: Clin Infect Dis. 2007 Apr 1;44(7):988-95
references: 17342655